Aktienanalyse zu ADICET Bio, Inc. (ACET)ACETADICET Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Adicet Bio Inc is not a good buy right now due to its current price of $3.02, which is significantly below its 52-week high of $11.20, indicating a 73% decline. Additionally, the RSI is at a very low 18.16, suggesting the stock is oversold, but the negative sentiment is strong with a year-to-date change of -65.76%. The main risk is the company's ongoing net losses, with a reported net income loss of $21.36 million for Q2 2026, which raises concerns about its financial stability.

4 analysts cover ACET: 2 rate it Buy, 2 Hold and 0 Sell. The average price target is 29.33.